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EDITORIAL
Identifying and addressing potentially preventable causes of
renal allograft loss
Despite increasing short- and long-term graft survival International, Matas et al identify and quantitate the
[1], our national kidney transplant waiting list has ex- relative importance of five “potentially preventable”
ceeded the 50,000 patient barrier and is expected to causes of graft loss in the 1990s compared to earlier
double by the year 2008. Median wait times currently decades [2].
exceed 4 years for both O and B blood types. The ne- Graft thrombosis rates are reported to have essentially
phrology community has become a victim of its own remained unchanged. Identifying patients who will have
success. Dialysis patients and their medical personnel a thrombosis is extremely difficult. Measurable titers of
have increasingly recognized that kidney transplantation antiphospholipid antibodies does not guarantee a throm-
is the superior modality of renal replacement therapy. botic event nor does their absence suggest safety. A
These perceptions are supported by data demonstrating strong family history, a past thrombotic event(s) (e.g.,
greater longevity and better quality of life in transplant prior transplant/dialysis access) and thrombus associated
recipients when compared to those patients who remain co-morbidities (e.g., lupus) are not contraindications to
on the waiting list. Perhaps simple economic principles transplantation, but may require prophylactic anticoagu-
should be our guide toward resolution of this burgeoning lation at the time of surgery. The risks of lifelong antico-
dilemma. Transplant surgeons, nephrologists, and na- agulation therapy versus the benefits of renal trans-
tional policy makers alike must carefully identify appro- plantation should be discussed in great detail before the
priate candidates while increasing their efforts to supply potential recipient agrees to receive a transplanted
organs. kidney.
The majority of efforts to this end, both by the trans- The falling relative significance of acute rejection as
plant community and public policy makers, have been a cause of graft loss is the result of an increased emphasis
to address issues on the supply side. Unfortunately, most on rejection prophylaxis, earlier diagnosis of, and better
policies have fallen short of their goals. The number therapies to reverse rejections that occur. The well-
of cadaveric organ transplants has remained essentially accepted association between acute rejection and the
static with only a small increase in organ procurement increased rate of chronic allograft nephropathy has led
over the past decade despite an organ donor card initia- to protocols with more intensive immunosuppressive
tive. Without legislation to protect transplant centers regimens.
from legal liability, centers may be obliged to accept the Chronic allograft nephropathy remains the bane of
wishes of a dissenting family member, against the will the transplant community. Significant manpower and fi-
of the potential donor. nancial resources have been allocated to combat this
One approach to diminish the growing disparity be- important cause of graft loss that often leads to retrans-
tween the number of available organs and deserving plantation. Correlations with acute rejection [3], infec-
transplantation candidates has been to increase the num- tion with cytomegalovirus [4], and cold ischemia time
ber of living donations through family education and [5] have led to strategies to minimize these risks. Matas
newer retrieval techniques. In 2001, for the first year in et al report an encouraging trend toward a reduction of
history, living donor transplants outnumbered cadaveric graft loss secondary to chronic allograft nephropathy [2].
transplants. Newer protocols that utilize potentially “non-nephro-
Strategies to decrease organ demand include pre- toxic” agents and the recognized underutilization of an-
venting and attempting to slow the progression of renal giotensin-converting enzyme (ACE) inhibitors and an-
disease, ensuring the physical and mental health of recip- giotensin II receptor blockers may further decrease
ient candidates, and increasing the half-lives of trans- future graft loss from chronic allograft nephropathy.
planted allografts, thereby reducing the number of pa- The significance of patient noncompliance as a cause
tients requiring retransplantation. In this issue of Kidney of graft loss cannot be understated. Noncompliance, at
least partially, accounts for 10-12% of graft loss [2]. A
prior history of noncompliance with treatment regimens,Key words: kidney transplant, quality of life, graft thrombosis, acute
rejection. certain degrees of mental illness, and continuing poly-
substance abuse without a prolonged period of absti- 2002 by the International Society of Nephrology
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nence forebode post-transplant noncompliance. Unfor- work should serve as a nidus for a formal review of the
national registry to confirm the etiologies of graft losstunately, only 7% of transplant centers surveyed have
and to elucidate areas to devote resources for improve-a formal pretransplantation psychosocial evaluation of
ment.potential recipients[6].
Perhaps the most alarming recognized trend is the
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